OBJECT: The authors studied the expression of angiogenic and growth factors and various proliferative indices in cavernous angiomas of the brain. The goal was to define whether the often progressive clinical course of both sporadic and familial forms of the lesion is correlated with different expression of these factors. METHODS: Forty-three cavernomas of the brain were investigated with immunohistochemical studies and stained for four growth factors (vascular endothelial growth factor [VEGF], tenascin, transforming growth factor-b [TGFb], and platelet-derived growth factor [PDGF]), and for Ki-67 and bcl-2. The intensity of expression was tested in all cases in the walls of cavernoma vessels, in the perivascular tissue, and in the perilesional brain parenchyma. Among the 43 cavernomas, 32 were stable and sporadic single lesions less than 2 cm in size, whereas 11 were cavernomas larger than 2 cm (up to 6 cm). These larger cavernomas had more aggressive behavior (documented growth in five cases, mass effect in eight, significant hemorrhage in four), familial occurrence (six cases), and/or multiple lesions (five cases). The expression of VEGF, tenascin, and PDGF in cavernomas did not significantly differ in the two groups of patients, whereas TGFb expression was higher in the more aggressive forms of cavernomas. The expression of Ki-67 and bcl-2 was always absent in stable lesions, and it was positive in eight (72.7%) of 11 aggressive lesions. The perilesional brain parenchyma showed a significantly higher expression of TGFb, PDGF, and tenascin in more aggressive cavernomas. CONCLUSIONS: The familial occurrence and more aggressive clinical behavior of cavernous angiomas of the brain are associated with higher expression of Ki-67 and bcl-2 in the cavernoma tissue, as in other proliferative lesions. These features are also associated with higher expression of some growth factors (excluding VEGF) in the perilesional brain parenchyma, suggesting that the neighboring vasculature and glia may be predisposed to and recruited for further growth and progression.
OBJECT: The authors studied the expression of angiogenic and growth factors and various proliferative indices in cavernous angiomas of the brain. The goal was to define whether the often progressive clinical course of both sporadic and familial forms of the lesion is correlated with different expression of these factors. METHODS: Forty-three cavernomas of the brain were investigated with immunohistochemical studies and stained for four growth factors (vascular endothelial growth factor [VEGF], tenascin, transforming growth factor-b [TGFb], and platelet-derived growth factor [PDGF]), and for Ki-67 and bcl-2. The intensity of expression was tested in all cases in the walls of cavernoma vessels, in the perivascular tissue, and in the perilesional brain parenchyma. Among the 43 cavernomas, 32 were stable and sporadic single lesions less than 2 cm in size, whereas 11 were cavernomas larger than 2 cm (up to 6 cm). These larger cavernomas had more aggressive behavior (documented growth in five cases, mass effect in eight, significant hemorrhage in four), familial occurrence (six cases), and/or multiple lesions (five cases). The expression of VEGF, tenascin, and PDGF in cavernomas did not significantly differ in the two groups of patients, whereas TGFb expression was higher in the more aggressive forms of cavernomas. The expression of Ki-67 and bcl-2 was always absent in stable lesions, and it was positive in eight (72.7%) of 11 aggressive lesions. The perilesional brain parenchyma showed a significantly higher expression of TGFb, PDGF, and tenascin in more aggressive cavernomas. CONCLUSIONS: The familial occurrence and more aggressive clinical behavior of cavernous angiomas of the brain are associated with higher expression of Ki-67 and bcl-2 in the cavernoma tissue, as in other proliferative lesions. These features are also associated with higher expression of some growth factors (excluding VEGF) in the perilesional brain parenchyma, suggesting that the neighboring vasculature and glia may be predisposed to and recruited for further growth and progression.
Authors: Romuald Girard; Hussein A Zeineddine; Maged D Fam; Anoop Mayampurath; Ying Cao; Changbin Shi; Robert Shenkar; Sean P Polster; Michael Jesselson; Ryan Duggan; Abdul-Ghani Mikati; Gregory Christoforidis; Jorge Andrade; Kevin J Whitehead; Dean Y Li; Issam A Awad Journal: Transl Stroke Res Date: 2017-08-17 Impact factor: 6.829
Authors: Xiaowei Zou; Blaine L Hart; Marc Mabray; Mary R Bartlett; Wei Bian; Jeffrey Nelson; Leslie A Morrison; Charles E McCulloch; Christopher P Hess; Janine M Lupo; Helen Kim Journal: Neuroradiology Date: 2017-05-22 Impact factor: 2.804
Authors: Romuald Girard; Hussein A Zeineddine; Janne Koskimäki; Maged D Fam; Ying Cao; Changbin Shi; Thomas Moore; Rhonda Lightle; Agnieszka Stadnik; Kiranj Chaudagar; Sean Polster; Robert Shenkar; Ryan Duggan; David Leclerc; Kevin J Whitehead; Dean Y Li; Issam A Awad Journal: Circ Res Date: 2018-05-02 Impact factor: 17.367
Authors: Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg Journal: J Clin Invest Date: 2021-07-01 Impact factor: 19.456
Authors: Bjoern Sommer; Burkhard Sebastian Kasper; Roland Coras; Ingmar Blumcke; Hajo Martinus Hamer; Michael Buchfelder; Karl Roessler Journal: Neurol Res Date: 2013-09-30 Impact factor: 2.448